| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3996534 | Practical Radiation Oncology | 2016 | 7 Pages |
Abstract
Even with risk-adapted fractionation, tumors abutting PBT are associated with a significant and differential risk of SBRT-related toxicity and death. SBRT should be used with particular caution in central-abutting tumors, especially in the context of anti-vascular endothelial growth factor therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Justin M. BSE, Andreas MD, Daphna Y. MD, Ankit MD, Kenneth E. MD, Andrew PhD, Ellen D. PhD, Abraham J. MD,